Cipla Ltd receives 1 observation from USFDA for Kurkumbh facility

Cipla Ltd has announced that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at manufacturing facility of the Company located in Kurkumbh, Maharashtra, India from 29th April, 2024 to 8th May, 2024.

On conclusion of the inspection, the Company has received 1 inspectional observation in Form 483. The Company will work closely with the USFDA and is committed to address this observation comprehensively within stipulated time.

Shares of Cipla Limited was last trading in BSE at Rs. 1384.80 as compared to the previous close of Rs. 1387.90. The total number of shares traded during the day was 97414 in over 2863 trades.

The stock hit an intraday high of Rs. 1398.85 and intraday low of 1375.40. The net turnover during the day was Rs. 135530188.00.

Source : Equity Bulls

Keywords

Cipla INE059A01026 USFDA Form483 1Observation Kurkumbh